[PDF] Top 20 DC based cancer vaccines

... Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful ... See full document

... of DC with tumour cells. Human clinical trials of tumour antigen loaded DC have been initiated for the treatment of B-cell lymphoma, prostate cancer melanoma and renal cell ...of ... See full document

... with cancer-specific neoantigens have been reported in melanoma patients using different vaccination strategies ...with DC loaded with peptides encompassing the neoantigen mutations (NCT00683670) ...peptide ... See full document

... RNA vaccines, and the limitations of the protected but inefficient delivery of RNA-liposomal ...against DC receptors CD11c or DEC-205 attached to liposome surfaces, demonstrating efficient DC ... See full document

... (CRT). DC vaccines pulsed with MDA-treated tumor cell lysates had a significant effect on tumor growth, showed cytotoxic T-lymphocyte activity against tumors, and increased the survival rate of test ... See full document

... breast cancer vaccine (77, 115, ...a cancer vaccine (120, 164) or as stand-alone im- munotherapeutics, eliciting an immune response to tumor self- antigens (17, 100, ...a DC-based vaccine ... See full document

... therapeutic cancer vaccines. DC-based immunotherapy has been reported to induce strong antitumor immune responses in animal experiments and in selected clinical trials involving malignant ... See full document

... cells compared to CpG, and was shown to significantly inhibit tumor progression in mice. In addition, liposomes also represent a particularly attractive approach due to the fact that they are synthetic phospholipid ... See full document

... as DC, B cells and T cells as well as non-immune ...promote DC maturation, including the up-regulation of MHC and costimulatory ...In cancer immunotherapy, a phase III clinical trial combining ... See full document

... ovarian cancer by ...another DC-based vaccine used in the identify antigenic system where MHC-I-restricted Wilms tumourgen 1 peptide antigens are incubated with the PBMDs of patients ...ovarian ... See full document

... of DC are well suited for the T cell activation protocol with NP encapsulated Ag we describe ...by DC/PLGA-OVA stimulation of cell cultures containing lower amounts (between 1–10%) of OVA-specific T cells ... See full document

... in cancer immunotherapy approaches ...in DC based active immunotherapy, since in vivo the percentages of survivin specific T cells will most likely remain below the ‘fratricide ... See full document

... expressing cancer-associated antigens? First, all the vaccine-targeted antigens (CEA, PSA, or 5 T4) represent non-mutated se- quences, which have typically exhibited low immunogen- icity, linked to weak immune ... See full document

... Strengths of the MACVAC trial include that it was a randomized trial, all patients received their assigned treat- ment, all patients were followed until death or for five years, and no patients were lost to follow up. ... See full document

... by different HA/NA ratios between wild-type and H6NX viruses or by differences in the affinities of the HAs toward the substrate (see above), and it is unclear whether this also occurs with polyclonal sera. Nevertheless, ... See full document

... Influenza virus belongs to the family Orthomyxoviridae and possesses eight-segmented, negative sense single stranded RNA. Influenza type A viruses are subcategorized into various subtypes based on distinct ... See full document

... this cancer, wild populations of the Tasmanian devil have been significantly reduced in Tasmania where the possibility of extinction either locally within 10–15 years [24, 25] or com- pletely within 25–35 years ... See full document

... bidirectional dc to dc to converter is advantageous as it enhances the signal and helps in boosting the voltage obtained from the output of the photovoltaic ... See full document

... The concept of activating the immune system of patient against the cancer has been proposed long ego.. William Coley was the first person to start a trial on immunotherapy for the treatment of cancer in ... See full document

... ing the immune system to direct an effective and long-term immune response against BC cells through the administration of a vaccine is an attractive strategy. Tumor vac- cination would have several theoretical advantages ... See full document